{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T15:01:11Z","timestamp":1749999671149},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T00:00:00Z","timestamp":1588636800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T00:00:00Z","timestamp":1588636800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s40266-020-00765-y","type":"journal-article","created":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T01:03:20Z","timestamp":1588640600000},"page":"469-481","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Management of Older Adults with Mantle Cell Lymphoma"],"prefix":"10.1007","volume":"37","author":[{"given":"Jason T.","family":"Romancik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathon B.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,5]]},"reference":[{"issue":"19","key":"765_CR1","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","volume":"117","author":"E Campo","year":"2011","unstructured":"Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019\u201332.","journal-title":"Blood"},{"issue":"5","key":"765_CR2","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/bjh.14699","volume":"181","author":"N Epperla","year":"2018","unstructured":"Epperla N, Hamadani M, Fenske TS, Costa LJ. Incidence and survival trends in mantle cell lymphoma. Br J Haematol. 2018;181(5):703\u20136.","journal-title":"Br J Haematol"},{"issue":"8","key":"765_CR3","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2008.19.6121","volume":"27","author":"P Martin","year":"2009","unstructured":"Martin P, Chadburn A, Christos P, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol. 2009;27(8):1209\u201313.","journal-title":"J Clin Oncol"},{"issue":"15","key":"765_CR4","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1002\/cncr.30068","volume":"122","author":"JB Cohen","year":"2016","unstructured":"Cohen JB, Han X, Jemal A, Ward EM, Flowers CR. Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma. Cancer. 2016;122(15):2356\u201363.","journal-title":"Cancer"},{"key":"765_CR5","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood.V128.22.22.22","volume":"128","author":"A Kumar","year":"2016","unstructured":"Kumar A, Ying Z, Alperovich A, et al. Outcome of initial observation in mantle cell lymphoma. Blood. 2016;128:22.","journal-title":"Blood"},{"issue":"3","key":"765_CR6","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjh.14241","volume":"175","author":"CW Eskelund","year":"2016","unstructured":"Eskelund CW, Kolstad A, Jerkeman M, et al. 15-year follow-up of the second nordic mantle cell lymphoma trial (MCL2): prolonged remissions without survival plateau. Br J Haematol. 2016;175(3):410\u20138.","journal-title":"Br J Haematol"},{"issue":"1","key":"765_CR7","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/bjh.13796","volume":"172","author":"D Chihara","year":"2016","unstructured":"Chihara D, Cheah CY, Westin JR, et al. Rituximab plus hyper-CVAD alternating with MTX\/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center. Br J Haematol. 2016;172(1):80\u20138.","journal-title":"Br J Haematol"},{"issue":"12","key":"765_CR8","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s40266-018-0596-5","volume":"35","author":"Z Al-Mansour","year":"2018","unstructured":"Al-Mansour Z, Ramanathan M, Cerny J. Hematopoietic cell transplant (HCT) in the elderly: myths, controversies, and unknowns. Drugs Aging. 2018;35(12):1055\u201364.","journal-title":"Drugs Aging"},{"issue":"6","key":"765_CR9","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","volume":"367","author":"HC Kluin-Nelemans","year":"2012","unstructured":"Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012;367(6):520\u201331.","journal-title":"N Engl J Med"},{"issue":"3","key":"765_CR10","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1200\/JCO.19.01294","volume":"38","author":"HC Kluin-Nelemans","year":"2020","unstructured":"Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle cell lymphoma (MCL): long-term follow-up of the randomized European MCL elderly trial. J Clin Oncol. 2020;38(3):248\u201356.","journal-title":"J Clin Oncol"},{"issue":"9873","key":"765_CR11","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203\u201310.","journal-title":"Lancet"},{"issue":"8","key":"765_CR12","first-page":"543","volume":"12","author":"P Hesketh","year":"2004","unstructured":"Hesketh P, Batchelor D, Golant M, Lyman G, Rhodes N, Yardley D. Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches. Support Care Cancer. 2004;12(8):543\u20139.","journal-title":"Support Care Cancer"},{"issue":"19","key":"765_CR13","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","volume":"123","author":"IW Flinn","year":"2014","unstructured":"Flinn IW, van der Jagt R, Kahl BS, et al. Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123(19):2944\u201352.","journal-title":"Blood"},{"issue":"10044","key":"765_CR14","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"O Hermine","year":"2016","unstructured":"Hermine O, Hoster E, Walewski J, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016;388(10044):565\u201375.","journal-title":"Lancet"},{"issue":"7","key":"765_CR15","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","volume":"112","author":"CH Geisler","year":"2008","unstructured":"Geisler CH, Kolstad A, Laurell A, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo\u2013purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood. 2008;112(7):2687\u201393.","journal-title":"Blood"},{"issue":"11","key":"765_CR16","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1200\/JCO.2012.45.9842","volume":"31","author":"C Visco","year":"2013","unstructured":"Visco C, Finotto S, Zambello R, et al. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. J Clin Oncol. 2013;31(11):1442\u20139.","journal-title":"J Clin Oncol"},{"issue":"1","key":"765_CR17","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2352-3026(16)30185-5","volume":"4","author":"C Visco","year":"2017","unstructured":"Visco C, Chiappella A, Nassi L, et al. Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. Lancet Haematol. 2017;4(1):e15\u2013e23.","journal-title":"Lancet Haematol"},{"issue":"1","key":"765_CR18","doi-asserted-by":"crossref","first-page":"13544","DOI":"10.1038\/s41598-019-49776-9","volume":"9","author":"S Ratnasingam","year":"2019","unstructured":"Ratnasingam S, Casan J, Shortt J, et al. Cytarabine-based induction immunochemotherapy in the front-line treatment of older patients with mantle cell lymphoma. Sci Rep. 2019;9(1):13544.","journal-title":"Sci Rep"},{"issue":"28","key":"765_CR19","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","volume":"23","author":"JE Romaguera","year":"2005","unstructured":"Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol. 2005;23(28):7013\u201323.","journal-title":"J Clin Oncol"},{"issue":"3","key":"765_CR20","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1365-2141.2005.05777.x","volume":"131","author":"D Bauwens","year":"2005","unstructured":"Bauwens D, Maerevoet M, Michaux L, et al. Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphoma. Br J Haematol. 2005;131(3):338\u201340.","journal-title":"Br J Haematol"},{"issue":"6","key":"765_CR21","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ctrv.2005.05.007","volume":"31","author":"E Kimby","year":"2005","unstructured":"Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev. 2005;31(6):456\u201373.","journal-title":"Cancer Treat Rev"},{"issue":"18","key":"765_CR22","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1182\/blood-2011-04-348367","volume":"118","author":"R Griffiths","year":"2011","unstructured":"Griffiths R, Mikhael J, Gleeson M, Danese M, Dreyling M. Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma. Blood. 2011;118(18):4808\u201316.","journal-title":"Blood"},{"issue":"2","key":"765_CR23","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3324\/haematol.2015.128710","volume":"101","author":"S Rule","year":"2016","unstructured":"Rule S, Smith P, Johnson PWM, et al. The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial. Haematologica. 2016;101(2):235\u201340.","journal-title":"Haematologica"},{"issue":"9","key":"765_CR24","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"G Lenz","year":"2005","unstructured":"Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the german low grade lymphoma study group (GLSG). J Clin Oncol. 2005;23(9):1984\u201392.","journal-title":"J Clin Oncol"},{"issue":"9","key":"765_CR25","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/jnci\/djk152","volume":"99","author":"H Schulz","year":"2007","unstructured":"Schulz H, Bohlius JF, Trelle S, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2007;99(9):706\u201314.","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"765_CR26","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1200\/JCO.2005.04.164","volume":"23","author":"M Ghielmini","year":"2005","unstructured":"Ghielmini M, Schmitz S, Cogliatti S, et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol. 2005;23(4):705\u201311.","journal-title":"J Clin Oncol."},{"issue":"9","key":"765_CR27","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.3109\/10428194.2011.580404","volume":"52","author":"VP Kenkre","year":"2011","unstructured":"Kenkre VP, Long WL, Eickhoff JC, et al. Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network. Leuk Lymphoma. 2011;52(9):1675\u201380.","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"765_CR28","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1182\/blood-2013-08-523845","volume":"123","author":"JE Chang","year":"2014","unstructured":"Chang JE, Li H, Smith MR, et al. Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405). Blood. 2014;123(11):1665\u2013733.","journal-title":"Blood"},{"issue":"11","key":"765_CR29","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1093\/annonc\/mdv364","volume":"26","author":"SA Graf","year":"2015","unstructured":"Graf SA, Stevenson PA, Holmberg LA, et al. Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma. Ann Oncol. 2015;26(11):2323\u20138.","journal-title":"Ann Oncol"},{"issue":"13","key":"765_CR30","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","volume":"377","author":"S Le Gouill","year":"2017","unstructured":"Le Gouill S, Thieblemont C, Oberic L, et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017;377(13):1250\u201360.","journal-title":"N Engl J Med"},{"issue":"15 Suppl","key":"765_CR31","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.1200\/JCO.2016.34.15_suppl.7503","volume":"34","author":"MJ Rummel","year":"2016","unstructured":"Rummel MJ, Knauf W, Goerner M, et al. Two years rituximab maintenance vs. observation after first-line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: First results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial). J Clin Oncol. 2016;34(15 Suppl):7503\u20137503.","journal-title":"J Clin Oncol."},{"issue":"3","key":"765_CR32","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1200\/JCO.2005.11.030","volume":"23","author":"SV Rajkumar","year":"2005","unstructured":"Rajkumar SV, Richardson PG, Hideshima T, Anderson KC. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol. 2005;23(3):630\u20139.","journal-title":"J Clin Oncol"},{"issue":"5","key":"765_CR33","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrc1361","volume":"4","author":"J Adams","year":"2004","unstructured":"Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer. 2004;4(5):349\u201360.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"765_CR34","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4049\/jimmunol.171.1.88","volume":"171","author":"LV Pham","year":"2003","unstructured":"Pham LV, Tamayo AT, Yoshimura LC, Lo P, Ford RJ. Inhibition of constitutive NF-\u03baB activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol. 2003;171(1):88\u201395.","journal-title":"J Immunol"},{"issue":"4","key":"765_CR35","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","volume":"23","author":"A Goy","year":"2005","unstructured":"Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2005;23(4):667\u201375.","journal-title":"J Clin Oncol"},{"issue":"1","key":"765_CR36","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2141.2008.07466.x","volume":"145","author":"OA O\u2019Connor","year":"2009","unstructured":"O\u2019Connor OA, Moskowitz C, Portlock C, et al. Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre phase 2 clinical trial. Br J Haematol. 2009;145(1):34\u20139.","journal-title":"Br J Haematol"},{"issue":"30","key":"765_CR37","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","volume":"24","author":"RI Fisher","year":"2006","unstructured":"Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006;24(30):4867\u201374.","journal-title":"J Clin Oncol"},{"issue":"3","key":"765_CR38","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdn656","volume":"20","author":"A Goy","year":"2008","unstructured":"Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol. 2008;20(3):520\u20135.","journal-title":"Ann Oncol"},{"issue":"1","key":"765_CR39","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/bjh.13101","volume":"168","author":"M Furtado","year":"2015","unstructured":"Furtado M, Johnson R, Kruger A, Turner D, Rule S. Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma. Br J Haematol. 2015;168(1):55\u201362.","journal-title":"Br J Haematol"},{"issue":"10","key":"765_CR40","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1182\/blood-2010-11-314708","volume":"117","author":"JW Friedberg","year":"2011","unstructured":"Friedberg JW, Vose JM, Kelly JL, et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed\/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood. 2011;117(10):2807\u201312.","journal-title":"Blood"},{"issue":"10","key":"765_CR41","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1412096","volume":"372","author":"T Robak","year":"2015","unstructured":"Robak T, Huang H, Jin J, et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med. 2015;372(10):944\u201353.","journal-title":"N Engl J Med"},{"issue":"11","key":"765_CR42","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S1470-2045(18)30685-5","volume":"19","author":"T Robak","year":"2018","unstructured":"Robak T, Jin J, Pylypenko H, et al. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. Lancet Oncol. 2018;19(11):1449\u2013588.","journal-title":"Lancet Oncol"},{"issue":"1","key":"765_CR43","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3324\/haematol.2018.191429","volume":"104","author":"R Gressin","year":"2019","unstructured":"Gressin R, Daguindau N, Tempescul A, et al. A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma. Haematologica. 2019;104(1):138\u201346.","journal-title":"Haematologica"},{"issue":"Suppl 1","key":"765_CR44","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1182\/blood-2018-99-112655","volume":"132","author":"LD Kaplan","year":"2018","unstructured":"Kaplan LD, Maurer MJ, Stock W, et al. Bortezomib maintenance (BM) or consolidation (BC) following aggressive immunochemotherapy and autologous stem cell transplant (ASCT) for untreated mantle cell lymphoma (MCL): 8 year follow up of CALGB 50403 (alliance). Blood. 2018;132(Suppl 1):146.","journal-title":"Blood"},{"issue":"4","key":"765_CR45","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nrc1323","volume":"4","author":"JB Bartlett","year":"2004","unstructured":"Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer. 2004;4(4):314\u201322.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"765_CR46","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2141.2007.06841.x","volume":"140","author":"N Reddy","year":"2008","unstructured":"Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol. 2008;140(1):36\u201345.","journal-title":"Br J Haematol"},{"issue":"24","key":"765_CR47","doi-asserted-by":"crossref","first-page":"7254","DOI":"10.1158\/0008-5472.CAN-13-0750","volume":"73","author":"K Song","year":"2013","unstructured":"Song K, Herzog BH, Sheng M, et al. Lenalidomide inhibits lymphangiogenesis in preclinical models of mantle cell lymphoma. Cancer Res. 2013;73(24):7254\u201364.","journal-title":"Cancer Res"},{"issue":"19","key":"765_CR48","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1505237","volume":"373","author":"J Ruan","year":"2015","unstructured":"Ruan J, Martin P, Shah B, et al. Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma. N Engl J Med. 2015;373(19):1835\u201344.","journal-title":"N Engl J Med"},{"issue":"19","key":"765_CR49","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1182\/blood-2018-07-859769","volume":"132","author":"J Ruan","year":"2018","unstructured":"Ruan J, Martin P, Christos P, et al. Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma. Blood. 2018;132(19):2016\u201325.","journal-title":"Blood"},{"issue":"3","key":"765_CR50","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2141.2009.07626.x","volume":"145","author":"TM Habermann","year":"2009","unstructured":"Habermann TM, Lossos IS, Justice G, et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol. 2009;145(3):344\u20139.","journal-title":"Br J Haematol"},{"issue":"11","key":"765_CR51","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1093\/annonc\/mdt366","volume":"24","author":"PL Zinzani","year":"2013","unstructured":"Zinzani PL, Vose JM, Czuczman MS, et al. Long-term follow-up of lenalidomide in relapsed\/refractory mantle cell lymphoma: subset analysis of the NHL-003 study. Ann Oncol. 2013;24(11):2892\u20137.","journal-title":"Ann Oncol"},{"issue":"3","key":"765_CR52","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1470-2045(15)00559-8","volume":"17","author":"M Trn\u011bn\u00fd","year":"2016","unstructured":"Trn\u011bn\u00fd M, Lamy T, Walewski J, et al. Lenalidomide versus investigator\u2019s choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial. Lancet Oncol. 2016;17(3):319\u201331.","journal-title":"Lancet Oncol"},{"issue":"29","key":"765_CR53","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","volume":"31","author":"A Goy","year":"2013","unstructured":"Goy A, Sinha R, Williams ME, et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol. 2013;31(29):3688\u201395.","journal-title":"J Clin Oncol"},{"issue":"4","key":"765_CR54","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjh.13456","volume":"170","author":"A Goy","year":"2015","unstructured":"Goy A, Kalayoglu Besisik S, Drach J, et al. Longer-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed\/refractory mantle cell lymphoma treated with lenalidomide on MCL-001(EMERGE) pivotal trial. Br J Haematol. 2015;170(4):496\u2013503.","journal-title":"Br J Haematol"},{"issue":"1","key":"765_CR55","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13045-017-0537-5","volume":"10","author":"M Wang","year":"2017","unstructured":"Wang M, Schuster SJ, Phillips T, et al. Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed\/progressed after or were refractory\/intolerant to ibrutinib (MCL-004). J Hematol Oncol. 2017;10(1):171.","journal-title":"J Hematol Oncol"},{"issue":"7","key":"765_CR56","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(12)70200-0","volume":"13","author":"M Wang","year":"2012","unstructured":"Wang M, Fayad L, Wagner-Bartak N, et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1\/2 clinical trial. Lancet Oncol. 2012;13(7):716\u201323.","journal-title":"Lancet Oncol"},{"issue":"5","key":"765_CR57","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.3324\/haematol.2016.154211","volume":"102","author":"F Zaja","year":"2017","unstructured":"Zaja F, Ferrero S, Stelitano C, et al. Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the fondazione italiana linfomi. Haematologica. 2017;102(5):e203\u2013e206206.","journal-title":"Haematologica"},{"issue":"2","key":"765_CR58","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3109\/08830185.2012.664797","volume":"31","author":"JJ Buggy","year":"2012","unstructured":"Buggy JJ, Elias L. Bruton tyrosine kinase (BTK) and its role in B-cell malignancy. Int Rev Immunol. 2012;31(2):119\u201332.","journal-title":"Int Rev Immunol"},{"issue":"1","key":"765_CR59","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1200\/JCO.2012.44.4281","volume":"31","author":"A Wiestner","year":"2013","unstructured":"Wiestner A. Targeting B-Cell receptor signaling for anticancer therapy: the Bruton\u2019s tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies. J Clin Oncol. 2013;31(1):128\u201330.","journal-title":"J Clin Oncol"},{"issue":"3","key":"765_CR60","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s11899-012-0127-0","volume":"7","author":"VP Kenkre","year":"2012","unstructured":"Kenkre VP, Kahl BS. The future of B-cell lymphoma therapy: the B-cell receptor and its downstream pathways. Curr Hematol Malig Rep. 2012;7(3):216\u201320.","journal-title":"Curr Hematol Malig Rep"},{"issue":"38","key":"765_CR61","doi-asserted-by":"crossref","first-page":"25332","DOI":"10.18632\/oncotarget.25011","volume":"9","author":"MI Merolle","year":"2018","unstructured":"Merolle MI, Ahmed M, Nomie K, Wang ML. The B cell receptor signaling pathway in mantle cell lymphoma. Oncotarget. 2018;9(38):25332\u201341.","journal-title":"Oncotarget"},{"issue":"25","key":"765_CR62","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/blood-2014-10-604272","volume":"124","author":"JR McMullen","year":"2014","unstructured":"McMullen JR, Boey EJH, Ooi JYY, Seymour JF, Keating MJ, Tam CS. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood. 2014;124(25):3829\u201330.","journal-title":"Blood"},{"issue":"12","key":"765_CR63","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1080\/10428194.2018.1457149","volume":"59","author":"C Cheng","year":"2018","unstructured":"Cheng C, Woronow D, Nayernama A, Wroblewski T, Jones SC. Ibrutinib-associated ventricular arrhythmia in the FDA adverse event reporting system. Leuk Lymphoma. 2018;59(12):3016\u20137.","journal-title":"Leuk Lymphoma"},{"issue":"26","key":"765_CR64","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1182\/blood-2014-06-583294","volume":"124","author":"M Levade","year":"2014","unstructured":"Levade M, David E, Garcia C, et al. Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. Blood. 2014;124(26):3991\u20135.","journal-title":"Blood"},{"issue":"17","key":"765_CR65","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1182\/blood-2017-11-818286","volume":"131","author":"D Ghez","year":"2018","unstructured":"Ghez D, Calleja A, Protin C, et al. Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. Blood. 2018;131(17):1955\u20139.","journal-title":"Blood"},{"issue":"15","key":"765_CR66","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1182\/blood-2016-06-722991","volume":"128","author":"IE Ahn","year":"2016","unstructured":"Ahn IE, Jerussi T, Farooqui M, Tian X, Wiestner A, Gea-Banacloche J. Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib. Blood. 2016;128(15):1940\u20133.","journal-title":"Blood"},{"issue":"5","key":"765_CR67","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/cid\/ciy175","volume":"67","author":"T Varughese","year":"2018","unstructured":"Varughese T, Taur Y, Cohen N, et al. Serious infections in patients receiving ibrutinib for treatment of lymphoid cancer. Clin Infect Dis. 2018;67(5):687\u201392.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"765_CR68","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507\u201316.","journal-title":"N Engl J Med"},{"issue":"6","key":"765_CR69","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","volume":"126","author":"ML Wang","year":"2015","unstructured":"Wang ML, Blum KA, Martin P, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015;126(6):739\u201345.","journal-title":"Blood"},{"issue":"10020","key":"765_CR70","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","volume":"387","author":"M Dreyling","year":"2016","unstructured":"Dreyling M, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. 2016;387(10020):770\u20138.","journal-title":"Lancet"},{"issue":"12","key":"765_CR71","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1080\/10428194.2017.1326034","volume":"58","author":"G Hess","year":"2017","unstructured":"Hess G, Rule S, Jurczak W, et al. Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus. Leuk Lymphoma. 2017;58(12):2824\u201332.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"765_CR72","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(15)00438-6","volume":"17","author":"ML Wang","year":"2016","unstructured":"Wang ML, Lee H, Chuang H, et al. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol. 2016;17(1):48\u201356.","journal-title":"Lancet Oncol"},{"issue":"3","key":"765_CR73","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/bjh.15411","volume":"182","author":"P Jain","year":"2018","unstructured":"Jain P, Romaguera J, Srour SA, et al. Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed\/refractory mantle cell lymphoma (MCL). Br J Haematol. 2018;182(3):404\u201311.","journal-title":"Br J Haematol"},{"issue":"3","key":"765_CR74","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1016\/S2352-3026(18)30018-8","volume":"5","author":"M Jerkeman","year":"2018","unstructured":"Jerkeman M, Eskelund CW, Hutchings M, et al. Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial. Lancet Haematol. 2018;5(3):e109\u2013e116116.","journal-title":"Lancet Haematol"},{"issue":"10121","key":"765_CR75","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","volume":"391","author":"M Wang","year":"2018","unstructured":"Wang M, Rule S, Zinzani PL, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018;391(10121):659\u201367.","journal-title":"Lancet"},{"issue":"11","key":"765_CR76","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1038\/s41375-019-0575-9","volume":"33","author":"M Wang","year":"2019","unstructured":"Wang M, Rule S, Zinzani PL, et al. Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma. Leukemia. 2019;33(11):2762\u20136.","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"765_CR77","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1182\/blood-2018-99-117956","volume":"132","author":"Y Song","year":"2018","unstructured":"Song Y, Zhou KZD. Safety and activity of the investigational Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) in patients with mantle cell lymphoma from a phase 2 trial. Blood. 2018;132(Suppl 1):148.","journal-title":"Blood"},{"issue":"Suppl 1","key":"765_CR78","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1182\/blood-2018-99-117224","volume":"132","author":"CS Tam","year":"2018","unstructured":"Tam CS, Wang MSD. Updated safety and activity of the investigational bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) in patients with mantle cell lymphoma. Blood. 2018;132(Suppl 1):1592\u20131592.","journal-title":"Blood"},{"issue":"5","key":"765_CR79","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.3324\/haematol.2018.205229","volume":"104","author":"S Rule","year":"2019","unstructured":"Rule S, Dreyling M, Goy A, et al. Ibrutinib for the treatment of relapsed\/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis. Haematologica. 2019;104(5):e211\u2013e214214.","journal-title":"Haematologica"},{"issue":"6","key":"765_CR80","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/annonc\/mdv111","volume":"26","author":"CY Cheah","year":"2015","unstructured":"Cheah CY, Chihara D, Romaguera JE, et al. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol. 2015;26(6):1175\u20139.","journal-title":"Ann Oncol"},{"issue":"12","key":"765_CR81","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","volume":"127","author":"P Martin","year":"2016","unstructured":"Martin P, Maddocks K, Leonard JP, et al. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016;127(12):1559\u2013633.","journal-title":"Blood"},{"issue":"3","key":"765_CR82","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/(SICI)1098-2264(200003)27:3<285::AID-GCC9>3.0.CO;2-M","volume":"27","author":"M Bentz","year":"2000","unstructured":"Bentz M, Plesch A, Bullinger L, et al. t(11;14)-positive mantle cell lymphomas exhibit complex karyotypes and share similarities with B-cell chronic lymphocytic leukemia. Genes Chromosomes Cancer. 2000;27(3):285\u201394.","journal-title":"Genes Chromosomes Cancer"},{"issue":"8","key":"765_CR83","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","volume":"35","author":"MS Davids","year":"2017","unstructured":"Davids MS, Roberts AW, Seymour JF, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma. J Clin Oncol. 2017;35(8):826\u201333.","journal-title":"J Clin Oncol"},{"issue":"2","key":"765_CR84","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.3324\/haematol.2018.198812","volume":"104","author":"TA Eyre","year":"2019","unstructured":"Eyre TA, Walter HS, Iyengar S, et al. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy. Haematologica. 2019;104(2):e68\u2013e71.","journal-title":"Haematologica"},{"issue":"Suppl 1","key":"765_CR85","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1182\/blood-2019-128788","volume":"135","author":"C Portell","year":"2019","unstructured":"Portell C, Wages NA, Kahl BS, et al. Multi-institution phase I\/Ib continual re-assessment study to identify the optimal dose of of ibrutinib (IBR) and venetoclax (VEN) in relapsed or refractory mantle cell lymphoma (MCL). Blood. 2019;135(Suppl 1):1535.","journal-title":"Blood"},{"issue":"13","key":"765_CR86","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","volume":"378","author":"CS Tam","year":"2018","unstructured":"Tam CS, Anderson MA, Pott C, et al. Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma. N Engl J Med. 2018;378(13):1211\u201323.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"765_CR87","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood-2019-126619","volume":"134","author":"SM Handunnetti","year":"2019","unstructured":"Handunnetti SM, Anderson MA, Burbury K, et al. Three Year update of the phase II ABT-199 (Venetoclax) and ibrutinib in mantle cell lymphoma (AIM) study. Blood. 2019;134(Suppl 1):756.","journal-title":"Blood"},{"issue":"2","key":"765_CR88","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/bjh.15552","volume":"184","author":"DJ Andorsky","year":"2019","unstructured":"Andorsky DJ, Kolibaba KS, Assouline S, et al. An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma. Br J Haematol. 2019;184(2):215\u201322.","journal-title":"Br J Haematol"}],"container-title":["Drugs &amp; Aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-020-00765-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40266-020-00765-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-020-00765-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T17:52:16Z","timestamp":1696096336000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40266-020-00765-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,5]]},"references-count":88,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["765"],"URL":"https:\/\/doi.org\/10.1007\/s40266-020-00765-y","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,5]]},"assertion":[{"value":"5 May 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Jonathon B. Cohen reports grant funding from the Lymphoma Research Foundation, and receipt of consulting fees from Loxo, Aptitude, Seattle Genetics, Gilead, Astra Zeneca, and Cellectar. Jason T Romancik declares that he has no conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}